Covidien Recalls Weak Batch Of Diagnostic Agent

Law360, New York (July 10, 2009, 12:00 AM EDT) -- Covidien PLC has recalled one lot of its radiopharmaceutical diagnostic agent used to monitor red blood cell levels to prevent strokes and other health risks, a response to the company’s routine post-market testing that revealed the product was not potent enough.

The medical device manufacturer and health firm on Friday said it decided to voluntarily recall subsidiary Mallinckrodt Inc.’s Sodium Chromate Cr-51 Injection on June 23 and was working to collect vials from customers in the U.S., Canada and Mexico.

The company said it had accounted...
To view the full article, register now.